ARTICLE | Management Tracks
In new role, the VC aims to combine elements of academic background with industry knowledge to create and develop new medicines
By Paul Bonanos, Director of Biopharma Intelligence
April 18, 2024 12:17 AM UTC
Innovation leader Uwe Schoenbeck has left Pfizer for a VC role at Canaan, with the expectation of blending lessons from his prior roles in academia and industry to guide early-stage scientific findings along the pathway to becoming promising medicines.
Schoenbeck was SVP and CSO for external science and innovation at Pfizer Inc. (NYSE:PFE), where he led the pharma’s Centers for Therapeutic Innovation (CTI) program in recent years. That initiative, established in 2010, was designed to tighten ties between the pharma and academic scientists, working closely together at locations in San Francisco, Boston, San Diego and New York…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652137/after-years-guiding-pfizer-innovation-initiative-schoenbeck-takes-venture-role-at-canaan